EligibleTrials

AI-Based Mobile Intervention on Medication Non-Adherence and Transition

Recruiting · NCT07445074 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Central Florida

View the official record on ClinicalTrials.gov →
Epilepsy

Interventions studied

Medilepsy® Chatbot AI-EnhancedMedilepsy® Chatbot Standard

What this trial is about

This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA. Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.

Who can take part

Age range
14 Years to 24 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

2 locations listed across 1 US state.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.